GSK targets Syndivia’s prostate cancer ADC in £268m buy - Pharmaceutical Technology

GSK Acquires Syndivia's Prostate Cancer ADC

GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment.

Despite having its own ADC in development for prostate cancer, GSK is expanding its investment in the modality.

The gold standard of business intelligence.

GSK's move fuels the industry buzz for the promising anti-tumour modality.

Author's summary: GSK buys Syndivia's ADC for £268m.

more

Pharmaceutical Technology Pharmaceutical Technology — 2025-10-27

More News